Ontogen Corporation Announces Presentation at ACS On Validation of OntoCHROM(TM) System

Apr 02, 2001, 01:00 ET from Ontogen Corporation

    SAN DIEGO, April 2 /PRNewswire/ -- Ontogen Corporation presented drug
 discovery applications of its novel high-throughput chromatographic
 purification system for compound libraries at the 221st National Meeting and
 Exposition of the American Chemical Society.  The presentation covered the
 proprietary integration of robotics and super-critical fluid carbon dioxide
 (CO2) as the basis for a novel purification technology called the
 OntoCHROM(TM) system.  It has the demonstrated ability to purify 250 discrete
 compounds by chromatography in an 8-hour period with both significant and
 unprecedented advantages over existing methodology when applied to drug
 discovery research, not the least of which is the drastic reduction in organic
 solvent use.
     "Our ability to engineer and develop technology that accelerates the
 discovery process enables our scientists to focus on identifying and
 optimizing quality leads, and to work on building a broader pipeline in a more
 rapid and efficient manner," said Barry E. Toyonaga, Ph.D., Ontogen's
 president and chief executive officer.  "Ontogen's innovative approach to
 synthesis, purification and optimization gives us a key advantage over
 companies relying on commercially available technology to identify viable drug
 candidates."
     Small molecule libraries representing potential drug candidates are
 created through automated combinatorial and parallel synthesis.  As these
 libraries are generated and tested, purification of the compounds is necessary
 to provide more meaningful data and eliminate generation of false positives in
 high throughput biological screening (HTS).  Preparative high performance
 liquid chromatography (prep HPLC), a leading methodology for selective
 purification, carries its own drawbacks, such as inefficiencies in fraction
 collection and sample handling, as well as the significant amounts of solvent
 necessary to purchase, manipulate, and discard when processing the large
 libraries in use with today's high throughput methods.  Ontogen has solved
 this problem with its OntoCHROM(TM) system.  This instrument relies on
 super-critical fluid chromatography (SFC) using CO2 as the mobile phase.  The
 Ontogen strategy results in a purification process for large numbers of
 compounds without the need for large volumes of solvent and without the
 necessity of numerous collected fractions per purified compound, subsequent
 solvent evaporation and reformatting.
     The availability of pure compound libraries will, for the first time,
 allow meaningful structure activity relationships to be obtained on large
 libraries.  Knowing the identity, purity and quantity of material in each well
 along with the determined biological activity will allow a realistic
 assessment of the contributions of various structural features of the
 molecules to biological activity and expedite the optimization process.
 Additionally, screening with pure compounds is expected to make this new
 paradigm more efficient by reducing the number of false positives and reducing
 the number of resyntheses necessary to confirm bioactivity.  Ontogen uses the
 four-channel OntoCHROM(TM) system to accelerate its own research efforts.
 Ontogen's existing automated discovery technologies as well as those now under
 development are being made available directly through Ontogen's Technology
 Alliance program or indirectly through R&D partnerships.
 
     Ontogen Corporation, founded in 1992, is a rapidly growing drug
 development company with vigorous research programs aimed at the development
 of novel small molecule therapeutics and the creation of high-throughput
 discovery technologies.  Those technologies include proprietary and highly
 efficient methods of chemical synthesis, compound analysis, purification,
 biological screening and data analysis.  With immediate projects in the area
 of cancer therapy, diabetes and inflammation, Ontogen is successfully applying
 its automated discovery technologies to achieve R&D goals of its own internal
 programs and its pharmaceutical partners.  In its most advanced internal
 program, through its Toronto based Canadian subsidiary, Ontogen is conducting
 clinical trials of its OC144-093 drug candidate to reverse the effects of
 cancer chemotherapy related multidrug resistance.  Currently, Ontogen
 collaborates on some of its programs with Novo Nordisk and Boehringer
 Ingelheim.  For additional corporate information, visit the Ontogen website at
 http://www.ontogen.com.
 
     OntoBLOCK(TM) and OntoCHROM(TM) are trademarks of Ontogen Corporation.
 
 

SOURCE Ontogen Corporation
    SAN DIEGO, April 2 /PRNewswire/ -- Ontogen Corporation presented drug
 discovery applications of its novel high-throughput chromatographic
 purification system for compound libraries at the 221st National Meeting and
 Exposition of the American Chemical Society.  The presentation covered the
 proprietary integration of robotics and super-critical fluid carbon dioxide
 (CO2) as the basis for a novel purification technology called the
 OntoCHROM(TM) system.  It has the demonstrated ability to purify 250 discrete
 compounds by chromatography in an 8-hour period with both significant and
 unprecedented advantages over existing methodology when applied to drug
 discovery research, not the least of which is the drastic reduction in organic
 solvent use.
     "Our ability to engineer and develop technology that accelerates the
 discovery process enables our scientists to focus on identifying and
 optimizing quality leads, and to work on building a broader pipeline in a more
 rapid and efficient manner," said Barry E. Toyonaga, Ph.D., Ontogen's
 president and chief executive officer.  "Ontogen's innovative approach to
 synthesis, purification and optimization gives us a key advantage over
 companies relying on commercially available technology to identify viable drug
 candidates."
     Small molecule libraries representing potential drug candidates are
 created through automated combinatorial and parallel synthesis.  As these
 libraries are generated and tested, purification of the compounds is necessary
 to provide more meaningful data and eliminate generation of false positives in
 high throughput biological screening (HTS).  Preparative high performance
 liquid chromatography (prep HPLC), a leading methodology for selective
 purification, carries its own drawbacks, such as inefficiencies in fraction
 collection and sample handling, as well as the significant amounts of solvent
 necessary to purchase, manipulate, and discard when processing the large
 libraries in use with today's high throughput methods.  Ontogen has solved
 this problem with its OntoCHROM(TM) system.  This instrument relies on
 super-critical fluid chromatography (SFC) using CO2 as the mobile phase.  The
 Ontogen strategy results in a purification process for large numbers of
 compounds without the need for large volumes of solvent and without the
 necessity of numerous collected fractions per purified compound, subsequent
 solvent evaporation and reformatting.
     The availability of pure compound libraries will, for the first time,
 allow meaningful structure activity relationships to be obtained on large
 libraries.  Knowing the identity, purity and quantity of material in each well
 along with the determined biological activity will allow a realistic
 assessment of the contributions of various structural features of the
 molecules to biological activity and expedite the optimization process.
 Additionally, screening with pure compounds is expected to make this new
 paradigm more efficient by reducing the number of false positives and reducing
 the number of resyntheses necessary to confirm bioactivity.  Ontogen uses the
 four-channel OntoCHROM(TM) system to accelerate its own research efforts.
 Ontogen's existing automated discovery technologies as well as those now under
 development are being made available directly through Ontogen's Technology
 Alliance program or indirectly through R&D partnerships.
 
     Ontogen Corporation, founded in 1992, is a rapidly growing drug
 development company with vigorous research programs aimed at the development
 of novel small molecule therapeutics and the creation of high-throughput
 discovery technologies.  Those technologies include proprietary and highly
 efficient methods of chemical synthesis, compound analysis, purification,
 biological screening and data analysis.  With immediate projects in the area
 of cancer therapy, diabetes and inflammation, Ontogen is successfully applying
 its automated discovery technologies to achieve R&D goals of its own internal
 programs and its pharmaceutical partners.  In its most advanced internal
 program, through its Toronto based Canadian subsidiary, Ontogen is conducting
 clinical trials of its OC144-093 drug candidate to reverse the effects of
 cancer chemotherapy related multidrug resistance.  Currently, Ontogen
 collaborates on some of its programs with Novo Nordisk and Boehringer
 Ingelheim.  For additional corporate information, visit the Ontogen website at
 http://www.ontogen.com.
 
     OntoBLOCK(TM) and OntoCHROM(TM) are trademarks of Ontogen Corporation.
 
 SOURCE  Ontogen Corporation